Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biocure Technology Inc C.CURE.X

Alternate Symbol(s):  BICTF

Healthcare Biotechnology
Biocure Technology Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.

Recent & Breaking News (CSE:CURE.X)

Canadian Investment Regulatory Organization Trade Resumption - CURE.X

Canada NewsWire July 4, 2024

Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction

Newsfile September 18, 2023

Canadian Investment Regulatory Organization Trading Halt - CURE

Canada NewsWire September 14, 2023

Biocure Corporate Update

Newsfile March 25, 2022

Biocure Corporate Update and Financing

Newsfile December 2, 2021

Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia ("CLL") and Solid Tumor Cancers and Intent to Apply for Patents

Newsfile August 30, 2021

BioCure Technology Inc. Lists on the Frankfurt Stock Exchange and Completion of Issuer Sponsored Research Report

Newsfile August 3, 2021

BioCure Technology Inc. (CSE:CURE) provides corporate updates

John Ballem  July 22, 2021

BioCure Technology Inc. Announces New President, Appointment of Capital Markets Advisor and Grant of Stock Options

Newsfile July 22, 2021

BioCure Technology Inc. Announces Closing of Financing

Newsfile July 14, 2021

BioCure Technology Inc. Commences Dual Listing in Germany and Announces New Contracts

Newsfile June 28, 2021

BiocurePharm, Korea (BPK) Signs MOU With Symbasis GmbH to Develop CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL)

Newsfile January 4, 2021

BiocurePharm, Korea ("BPK") Announces the Submission of IND Application for Phase 1 Trial of CD19 CAR-T Therapy

Newsfile December 30, 2020

BioCure Technology Inc. Announces Closing of Financing

Newsfile October 14, 2020

BiocurePharm, Korea ("BPK") Signs MOU With S&R Biopharm Enabling Expansion Into The European CAR T Market

Newsfile September 21, 2020

BiocurePharm, Korea ("BPK") Provides Corporate Update

Newsfile September 10, 2020

BiocurePharm, Korea ("BPK") Announces Private Placement

Newsfile March 16, 2020

BiocurePharm, Korea ("BPK") Announces Private Placement

Newsfile January 20, 2020

BiocurePharm, Korea ("BPK") Announces Closing of Convertible Debenture Financing

Newsfile December 5, 2019

Biocure Enters into a Clinical Trial for CAR T -Cell Products in Korea

Newsfile October 17, 2019